Claire Jansson-Knodell, MD: Treating Pregnant Women With Celiac Disease
Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.
Jessica Allegretti, MD, MPH: An Update on the Quasar Study at DDW 2023
In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.
Guselkumab Bests Placebo in Clinical Remission for Ulcerative Colitis
Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.